加载中
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
收盘时
US$1.78
+US$0.02 · +1.14%
盘后
US$1.83
+US$0.05 · +2.81%
10月6日 16:44 ET
盘中时间采用ET。市场数据可能有所延迟。
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
日内区间
当前US$1.78
52周区间
当前US$1.78
盘中时间采用ET。市场数据可能有所延迟。
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
日内区间
当前US$1.78
52周区间
当前US$1.78
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 53.49万 USD | 51.67万 USD | 9.86万 USD | 4.25万 USD |
| 毛利 | — | −53.49万 USD | −51.67万 USD | −9.86万 USD | −4.25万 USD |
| 研究与开发 | 1342.18万 USD | 961.55万 USD | 1226.35万 USD | 1023.24万 USD | 275.4万 USD |
| 销售、一般及管理费用 | 577.11万 USD | 551.04万 USD | 663.82万 USD | 833.48万 USD | 335.47万 USD |
| 营业费用 | 2798.01万 USD | 1512.58万 USD | 1890.18万 USD | 1856.72万 USD | 610.87万 USD |
| 利息收入 | 7.92万 USD | 684 USD | 5285 USD | 2.04万 USD | 664 USD |
| 利息支出 | 6616 USD | 2.68万 USD | 5.59万 USD | 1756.5万 USD | 9.51万 USD |
| 折旧和摊销 | 11.42万 USD | 53.49万 USD | 51.67万 USD | 9.86万 USD | 4.25万 USD |
| 营业利润 | −2798.01万 USD | −1566.07万 USD | −1941.85万 USD | −1866.58万 USD | −615.11万 USD |
| 净利润 | −3466.11万 USD | −1675.5万 USD | −1854.61万 USD | −1756.5万 USD | −684.34万 USD |
公司数据更新于 2026年10月6日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
